FTC /TDF

PreclinicalSmall molecule

RRockefeller University

FTC /TDF is one of 11 small molecule programs targeting HIV-1. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HIV-1Completed

HIV-1Preclinical

Completed

Competition

Competitive Landscape

11 competitors in HIV-1

#DrugCompanyPhaseTrials

Cabenuva

GSK

Approved

4 2

Biktarvy

Gilead

Phase 3

3 3

Sunlenca

Gilead

Phase 3

1 4

B/F/TAF

Gilead

Phase 3

2 5

ISL/LEN

Gilead

Phase 3

1 6

VRC07-523LS

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 2

2 7

IM CAB LA

GSK

Phase 2

1 8

PGT121.414.LS

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 1

1 9

Thymopentin

IImmunobiology Research Institute

Preclinical

2 10

Sirtuin Histone Deacetylase Inhibitor

FFederal University of São Paulo

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

HIV-11 trial

Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)

Completed·RRockefeller University·N/A·NCT00525733·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for FTC /TDF. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FTC /TDF compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FTC /TDF. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Rockefeller University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: RRockefeller University

FTC /TDF

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

HIV-11 trial

References

Drug Info

Quick Facts

Related News